WO2004083231A3 - Utilisation de ligands peptidiques de recepteurs de la membrane plasmique et de leurs analogues pour moduler l'activite des mitochondries - Google Patents

Utilisation de ligands peptidiques de recepteurs de la membrane plasmique et de leurs analogues pour moduler l'activite des mitochondries Download PDF

Info

Publication number
WO2004083231A3
WO2004083231A3 PCT/FR2004/000578 FR2004000578W WO2004083231A3 WO 2004083231 A3 WO2004083231 A3 WO 2004083231A3 FR 2004000578 W FR2004000578 W FR 2004000578W WO 2004083231 A3 WO2004083231 A3 WO 2004083231A3
Authority
WO
WIPO (PCT)
Prior art keywords
similar
plasma membrane
mitochondrial activity
mitochondrial
peptide ligands
Prior art date
Application number
PCT/FR2004/000578
Other languages
English (en)
Other versions
WO2004083231A2 (fr
Inventor
Gerard Morel
Aude Debon
Cecile Vivancos
Original Assignee
Centre Nat Rech Scient
Univ Claude Bernard Lyon
Gerard Morel
Aude Debon
Cecile Vivancos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Claude Bernard Lyon, Gerard Morel, Aude Debon, Cecile Vivancos filed Critical Centre Nat Rech Scient
Publication of WO2004083231A2 publication Critical patent/WO2004083231A2/fr
Publication of WO2004083231A3 publication Critical patent/WO2004083231A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/184—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Ligand peptidique d'un récepteur de la membrane plasmique ou analogue, associés à un peptide d'adressage mitochondrial, comme médicament ou produit agroalimentaire modulateur de l'activité des mitochondries. Utilisations dans le traitement du cancer, de l'obésité, des maladies ou syndromes métaboliques, des troubles de la croissance, des maladies mitochondriales, de la nécrose et de la dégénération, et du vieillissement, ainsi que pour améliorer le développement et augmenter la masse musculaire et la production de lait, chez l'animal.
PCT/FR2004/000578 2003-03-11 2004-03-11 Utilisation de ligands peptidiques de recepteurs de la membrane plasmique et de leurs analogues pour moduler l'activite des mitochondries WO2004083231A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0302984 2003-03-11
FR0302984A FR2852247A1 (fr) 2003-03-11 2003-03-11 Utilisation de ligands peptidiques de recepteurs de la membrane plasmique et de leurs analogues pour moduler l'activite des mitochondries

Publications (2)

Publication Number Publication Date
WO2004083231A2 WO2004083231A2 (fr) 2004-09-30
WO2004083231A3 true WO2004083231A3 (fr) 2004-11-11

Family

ID=32893199

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2004/000578 WO2004083231A2 (fr) 2003-03-11 2004-03-11 Utilisation de ligands peptidiques de recepteurs de la membrane plasmique et de leurs analogues pour moduler l'activite des mitochondries

Country Status (2)

Country Link
FR (1) FR2852247A1 (fr)
WO (1) WO2004083231A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1393509B1 (it) * 2008-07-08 2012-04-27 Advanced Accelerator Applications S A Peptidi e loro uso come carrier in cellule cancerose

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2541271A1 (fr) * 1983-02-21 1984-08-24 Sanofi Sa Nouvelle synthese du hpgrf en phase liquide
EP0157753A1 (fr) * 1984-03-26 1985-10-09 TECHLAND, Société Anonyme Dérivés de la somatostatine, procédés de synthèse, préparation pour usage vétérinaire contenant ces dérivés et méthode pour le traitement d'animaux
EP0278103A2 (fr) * 1987-01-12 1988-08-17 American Cyanamid Company Préparations d'hormones de croissance à libération prolongée administrables par voie parentérale et leurs utilisations
US4828988A (en) * 1986-05-15 1989-05-09 Smith Kline - Rit Hybrid polypeptides comprising somatocrinine and alpha1 -antitrypsin, method for their production from bacterial clones and use thereof for the production of somatocrinine
WO1991005548A1 (fr) * 1989-10-10 1991-05-02 Pitman-Moore, Inc. Composition a liberation entretenue pour proteines macromoleculaires
WO2000057921A2 (fr) * 1999-02-19 2000-10-05 During Matthew J Therapie genique perorale des diabetes et de l'obesite
EP1097716A1 (fr) * 1999-11-03 2001-05-09 Chronolife Inc. Suppléments de nourriture diététique et médicaments contre l'adiposité à base de l'hormone de libération de la thyrotropine (TRH)
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US20020156010A1 (en) * 2000-11-20 2002-10-24 Lustig Robert H. Method of treating obesity in adult patients exhibiting primary insulin hypersecretion

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2541271A1 (fr) * 1983-02-21 1984-08-24 Sanofi Sa Nouvelle synthese du hpgrf en phase liquide
EP0157753A1 (fr) * 1984-03-26 1985-10-09 TECHLAND, Société Anonyme Dérivés de la somatostatine, procédés de synthèse, préparation pour usage vétérinaire contenant ces dérivés et méthode pour le traitement d'animaux
US4828988A (en) * 1986-05-15 1989-05-09 Smith Kline - Rit Hybrid polypeptides comprising somatocrinine and alpha1 -antitrypsin, method for their production from bacterial clones and use thereof for the production of somatocrinine
EP0278103A2 (fr) * 1987-01-12 1988-08-17 American Cyanamid Company Préparations d'hormones de croissance à libération prolongée administrables par voie parentérale et leurs utilisations
WO1991005548A1 (fr) * 1989-10-10 1991-05-02 Pitman-Moore, Inc. Composition a liberation entretenue pour proteines macromoleculaires
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
WO2000057921A2 (fr) * 1999-02-19 2000-10-05 During Matthew J Therapie genique perorale des diabetes et de l'obesite
EP1097716A1 (fr) * 1999-11-03 2001-05-09 Chronolife Inc. Suppléments de nourriture diététique et médicaments contre l'adiposité à base de l'hormone de libération de la thyrotropine (TRH)
US20020156010A1 (en) * 2000-11-20 2002-10-24 Lustig Robert H. Method of treating obesity in adult patients exhibiting primary insulin hypersecretion

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
H. BACHAR ET AL.: "Modulation of rat olfactory bulb mitochondrial function by atrial natriuretic peptide.", PFLÜGERS RCHIV EUROPEAN JOURNAL OF PHYSIOLOGY, vol. 422, no. 2, 1992, pages 204 - 206, XP008026982 *
P.E. LOBIE ET AL.: "Receptor-mediated nuclear translocation of growth hormone.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 33, 19 August 1994 (1994-08-19), BALTIMORE, MD, US, pages 21330 - 21339, XP002268793 *
P.V. CARROLL ET AL.: "Growth hormone therapy may benefit protein metabolism in mitochondrial encephalomyopathy.", CLINICAL ENDOCRINOLOGY, vol. 47, 1997, pages 113 - 117, XP002268792 *
SADIR RABIA ET AL: "Caveolae and clathrin-coated vesicles: Two possible internalization pathways for IFN-gamma and IFN-gamma receptor", CYTOKINE, vol. 14, no. 1, 7 April 2001 (2001-04-07), pages 19 - 26, XP002297046, ISSN: 1043-4666 *
SEAN C SWEETMAN: "Martindale, The complete drug reference", 2002, PHARMACEUTICAL PRESS, USA, XP002297047 *

Also Published As

Publication number Publication date
FR2852247A1 (fr) 2004-09-17
WO2004083231A2 (fr) 2004-09-30

Similar Documents

Publication Publication Date Title
WO2006042152A3 (fr) Produits pharmaceutiques a base de polypeptides intestinaux vasoactifs
WO2007044591A3 (fr) Produits pharmaceutiques a base de polypeptides intestinaux vasoactifs
TW200744642A (en) Novel peptides for use in the treatment of obesity
WO2006040129A3 (fr) Conjugues de proteine utilisables en therapie, pour le diagnostic et en chromatographie
EP2366715A3 (fr) Molécules chimère d'anticorps anti-RANKL et de PTH/PTHRP
WO2007062078A3 (fr) Composes modulant l'activite thrombopoietine et procedes correspondants
WO2007018797A8 (fr) Stimulation nerveuse selective pour le traitement de troubles de l'alimentation
WO2007118963A3 (fr) Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations
WO2006048777A3 (fr) Hormones de croissance modifiees
WO2007046006A3 (fr) Domaine sushi de l'il-15ralpha utilise en tant que renforçateur puissant de l'action de l'il-15 par l'intermediaire de l'il-15rbeta/gamma, et proteines de fusion hyperagonistes (ilralpha sushi-il 15)
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
EP1771188A4 (fr) Methodes et compositions destinees au traitement de l'obesite, de maladies associees a l'insuline et de l'hypercholesterolemie
WO2005105110A3 (fr) Analogues de doxepine et leurs procedes d'utilisation
WO2005070390A3 (fr) Solution orale de mitratapide
IL172733A0 (en) Diphenylpyridine derivatives, preparation and therapeutic application thereof
WO2004064806A3 (fr) Procede permettant de modifier la formation de cristaux medicamenteux
WO2002060419A3 (fr) Substance a utiliser dans un complement d'alimentation ou pour une preparation de medicament destine au traitement du diabete sucre non-insulinodependant, de l'hypertension et/ou du syndrome metabolique
AU2003267411A1 (en) Bitter taste receptors
AU2002258428A1 (en) Methods for the treatment of metabolic disorders, including obesity and diabetes
WO2007030944A3 (fr) Methodes de cardioprotection consistant a utiliser du dichloroacetate combine a un inotrope
WO2004084949A3 (fr) Production de promedicaments a base de proteines au moyen de liaisons ppg reversibles
AU2003221699A1 (en) Pharmaceutical preparation for taste masking
AU2002354269A1 (en) Pharmaceutical and foodstuff products comprising deuterium for the treatment of diabetes and methods for production thereof
WO2005105740A3 (fr) Préparation de tégasérode et de maléate de tégasérode
AU2003208673A1 (en) Pacifier for administering flavour substances

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase